Sionna director granted options on 17,340 shares

Sionna Therapeutics director Laurie Stelzer received a grant of non-qualified stock options covering 17,340 shares of common stock.

Rhea-AI Filing Summary

Sionna Therapeutics director Laurie Stelzer received a grant of non-qualified stock options covering 17,340 shares of common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036.

The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting, subject to her continued service. Following this grant, Stelzer holds options for 17,340 underlying shares directly, reflecting a routine equity-based compensation award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 17,340 shares

Grant/Award 1 txn

Insider Stelzer Laurie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	17,340	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 17,340 contracts (Direct)

Footnotes (1)

1. F1. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option shares granted: 17,340 shares Exercise price: $36.73 per share Expiration date: June 16, 2036 +2 more

5 metrics

Option shares granted 17,340 shares Non-qualified stock option grant to director Laurie Stelzer

Exercise price $36.73 per share Exercise price of non-qualified stock option

Expiration date June 16, 2036 Option expiration for director grant

Underlying common shares 17,340 shares Common stock underlying the option award

Total options after grant 17,340 shares Total derivative holdings following transaction

Key Terms

Non-Qualified Stock Option, grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price": "36.7300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"This option vests in full upon the earlier of June 17, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sionna Therapeutics (SION) director Laurie Stelzer receive in this Form 4?

Laurie Stelzer received a grant of non-qualified stock options for 17,340 shares of Sionna Therapeutics common stock. These options are a form of equity compensation, not an open-market purchase or sale of existing shares.

What is the exercise price of Laurie Stelzer’s new SION stock options?

The options granted to Laurie Stelzer have an exercise price of $36.73 per share. She can choose to buy Sionna Therapeutics common stock at this fixed price once the options vest, if she decides to exercise them.

When do Laurie Stelzer’s Sionna Therapeutics stock options vest?

The options vest in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting. Vesting is conditioned on Laurie Stelzer’s continued service through that vesting date.

When do the SION stock options granted to Laurie Stelzer expire?

The non-qualified stock options granted to Laurie Stelzer expire on June 16, 2036. After that expiration date she can no longer exercise the options to purchase Sionna Therapeutics common shares at the stated exercise price.

How many Sionna Therapeutics shares are covered by Laurie Stelzer’s new options?

The new option award covers 17,340 shares of Sionna Therapeutics common stock. This entire amount is reflected as her total derivative holdings following the transaction reported in the Form 4 filing.

Is Laurie Stelzer buying or selling SION shares in this Form 4 filing?

She is not buying or selling shares on the open market. The filing reports a grant of non-qualified stock options as compensation, giving her the right to buy 17,340 Sionna Therapeutics shares at $36.73 in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 05:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stelzer Laurie

(Last) (First) (Middle)

C/O SIONNA THERAPEUTICS, INC.

21 HICKORY DRIVE, SUITE 500

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sionna Therapeutics, Inc. [ SION ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$36.73	06/17/2026		A		17,340		(1)	06/16/2036	Common Stock	17,340	$0.0	17,340	D

Explanation of Responses:

1. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

	By: Jennifer Fitzpatrick, Attorney-in-Fact For: Laurie Stelzer	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)